Annals of Internal Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 14, 2025
Recent
trends
in
use
of
tirzepatide,
a
dual
glucagon-like
peptide-1
(GLP-1)
and
glucose-dependent
insulinotropic
polypeptide
receptor
agonist
(RA),
versus
other
glucose-lowering
medications
(GLMs)
weight-lowering
(WLMs)
remain
unexplored.
To
describe
insurance
claims
for
GLMs
WLMs
after
tirzepatide
approval.
Population-based
cohort
study.
Claims
data
from
large
U.S.
commercial
database
(January
2021
to
December
2023).
Adults
(aged
≥18
years)
with
type
2
diabetes
(T2D)
without
dispensations
WLMs.
Any
was
defined
as
medication
dispensation
regardless
prior
use.
Incident
the
preceding
year.
Monthly
before
market
entry.
Tirzepatide
uptake
additionally
compared
initial
postapproval
increased
markedly
among
adults
T2D
prescribed
GLMs,
reaching
12.3%
all
GLM
by
2023.
Similar
patterns
were
observed
sodium-glucose
cotransporter-2
inhibitors
(14.5%
24.4%)
GLP-1
RAs
(19.5%
28.5%).
Dispensations
including
metformin,
declined.
Among
but
WLMs,
(0.0%
40.6%)
semaglutide
(2.4
mg)
32.2%)
sharply,
(2.0
most
frequently
dispensed
WLM,
increasing
37.8%
45.7%.
incident
users.
more
rapid
sustained
periods
medications.
Generalizability
health
is
uncertain.
These
findings
highlight
sharp
entry
enhance
understanding
rapidly
shifting
landscape
prescribing
National
Institute
Diabetes
Digestive
Kidney
Diseases.
Pharmacy,
Journal Year:
2025,
Volume and Issue:
13(2), P. 46 - 46
Published: March 19, 2025
Health
disparities
affecting
minority
populations
and
resulting
in
poorer
outcomes
for
disadvantaged
groups
have
been
documented
the
literature.
Sodium/glucose-cotransporter
2
(SGLT2i)
inhibitors
GLP-1
receptor
agonists
(GLP-1RA)
markedly
decrease
mortality
from
kidney
cardiovascular
events.
However,
little
is
known
about
factors
that
lead
to
differences
SGLT2i
GLP-1RA
initiation
across
different
ethnic
groups.
This
scoping
review
queried
databases
using
key
terms
related
of
among
high-risk
populations.
Relevant
data
eligible
studies
were
extracted,
organized,
analyzed
thematically
identify
trends
patterns
Nineteen
included
this
review.
Key
risk
influencing
uptake
age,
provider
type,
race,
sex,
education,
comorbidities,
insurance,
income,
with
patients
consistently
showing
lower
rates
due
systemic
barriers
socioeconomic
disparities.
Patients
who
younger,
male,
had
higher
education
or
income
levels,
received
care
specialists
more
likely
use
these
therapies.
The
adoption
remains
suboptimal
despite
their
proven
benefits.
Targeted
efforts
reduce
racial
inequities
based
on
identified
should
be
encouraged.
Annals of Internal Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 14, 2025
Recent
trends
in
use
of
tirzepatide,
a
dual
glucagon-like
peptide-1
(GLP-1)
and
glucose-dependent
insulinotropic
polypeptide
receptor
agonist
(RA),
versus
other
glucose-lowering
medications
(GLMs)
weight-lowering
(WLMs)
remain
unexplored.
To
describe
insurance
claims
for
GLMs
WLMs
after
tirzepatide
approval.
Population-based
cohort
study.
Claims
data
from
large
U.S.
commercial
database
(January
2021
to
December
2023).
Adults
(aged
≥18
years)
with
type
2
diabetes
(T2D)
without
dispensations
WLMs.
Any
was
defined
as
medication
dispensation
regardless
prior
use.
Incident
the
preceding
year.
Monthly
before
market
entry.
Tirzepatide
uptake
additionally
compared
initial
postapproval
increased
markedly
among
adults
T2D
prescribed
GLMs,
reaching
12.3%
all
GLM
by
2023.
Similar
patterns
were
observed
sodium-glucose
cotransporter-2
inhibitors
(14.5%
24.4%)
GLP-1
RAs
(19.5%
28.5%).
Dispensations
including
metformin,
declined.
Among
but
WLMs,
(0.0%
40.6%)
semaglutide
(2.4
mg)
32.2%)
sharply,
(2.0
most
frequently
dispensed
WLM,
increasing
37.8%
45.7%.
incident
users.
more
rapid
sustained
periods
medications.
Generalizability
health
is
uncertain.
These
findings
highlight
sharp
entry
enhance
understanding
rapidly
shifting
landscape
prescribing
National
Institute
Diabetes
Digestive
Kidney
Diseases.
